Month: September 2022

NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a fireside chat at the Ladenburg Thalmann Healthcare Conference on Thursday, September 29, 2022 at 9:30 AM Eastern Time. The conference will be held at the Sofitel New York in New York City. A live webcast and archive of the event can be viewed on the “Webcasts & Presentations” page of the “Investors” section of the Company’s website at www.axsome.com. About Axsome Therapeutics, Inc.Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions...

~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~ RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2022 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved PEDMARK® (sodium thiosulfate injection) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors. This approval makes PEDMARK the first and only treatment approved by the FDA in this area of significant unmet medical need. “The FDA approval of PEDMARK represents an important breakthrough for pediatric patients with localized,...

PHILADELPHIA, Sept. 21, 2022 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), today announced three poster presentations highlighting its development program for Pompe disease will be included at the 2022 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting, being held September 21-24, 2022 in Nashville, TN and virtually. Poster Presentations:Abstract Title: Long-term follow-up of cipaglucosidase alfa/miglustat in ambulatory patients with Pompe disease: an open-label Phase I/II study (ATB200-02) (Poster #104)Presenter: Barry J. Byrne, MD, PhD, University of Florida, Gainesville, FL, U.S.A.Date and Time: Thursday, September 22, 6:00-6:30 p.m. CT and Friday, September 23, 3:30-4:00 p.m. CTLocation: Ryman Exhibit Hall B1Abstract Title: Immunogenicity of cipaglucosidase alfa/miglustat...

Paper describes key insight into integrin conformation, overcoming critical drug development challenge Company lauds Tim Springer, PhD, scientific founder of Morphic and Fu-Yang “Albert” Lin, PhD, first company employee WALTHAM, Mass., Sept. 21, 2022 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today recognized a pioneering publication in the journal Cell. This article describes the research that serves both as foundational understanding of integrin conformation to broadly inform integrin drug development and also served as the catalyst for the formation of Morphic Therapeutic. The central biologic role of the integrin family of receptors has long been understood. The publication details the...

CALGARY, Alberta, Sept. 21, 2022 (GLOBE NEWSWIRE) — Crew Energy Inc. (TSX: CR; OTCQB: CWEGF) (“Crew” or the “Company“), a growth-oriented natural gas weighted producer operating in the world-class Montney play in northeast British Columbia (“NE BC”), is pleased to announce that we have achieved independent certification of our natural gas and natural gas liquids production from our NE BC Development area under the Equitable Origin EO100™ Standard for Responsible Energy Development (the “Certification”). The Certification confirms Crew’s best-practice methods for environmental, social and governance (“ESG”) performance in the energy sector and demonstrates our commitment to continuous improvement. As part of the Certification process, a team of approved third-party assessors from AECOM Canada Ltd. conducted...

FRISCO, TX, Sept. 21, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Verde Bio Holdings, Inc. (OTCQB: VBHI) (www.verdebh.com), a growing oil and gas company, today announced that it has entered into an agreement with a private buyer for the sale of two of its assets for a combined sales price of $1,068,300. The transaction is scheduled to close on or before October 21, 2022, with an effective date of December 1, 2022, pending buyer due diligence. Verde Bio Holdings will achieve approximately a 78% profit with the sales price alone, which combined with revenue generated from holding the assets for a little over a year equates to a significant return to the company on its investment in the assets. In addition to the profits and previous revenue mentioned above, Verde also will receive all revenue of the assets related to production from...

NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) —  OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Strawberry Fields REIT, Inc. (OTCQX: STRW), a Real Estate Investment Trust specializing in buying and leasing senior healthcare facilities, has gone public on the OTCQX® Best Market. Strawberry Fields REIT, Inc. begins trading today on OTCQX under the symbol “STRW.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. The OTCQX Market offers private companies an efficient pathway to go public.  To qualify for OTCQX, companies must meet high financial standards, be current in their disclosure, follow best practice corporate governance, and demonstrate compliance with applicable securities...

Eric J. Ende, MD, MBA Appointed as Chairman, Effective October 1, 2022; Founding Chairman Herbert J. Conrad to Remain an Independent Director of the Company BEDMINSTER, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform delivery technology, today announced its leadership succession plan, with the Board of Directors unanimously appointing current board member, Eric J. Ende, to succeed Herbert J. Conrad as Chairman of the Board. Mr. Conrad, the founding Chairman of Matinas will remain on the Board as an independent director of the Company. The succession will be effective October 1, 2022. “This change is representative of...

VANCOUVER, British Columbia, Sept. 21, 2022 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has recently received a cash payment of approximately CDN $450K from a refundable tax credit program from its clinical research work in Australia. “Algernon tries to conduct as much of its clinical research in Australia as possible because of the 43.5% refundable R&D tax credit program,” said Christopher J. Moreau, CEO of Algernon. “This brings our total cash refund received to date to over CDN $3.0M, which has been an important part of Algernon’s capital efficient business model.” Additionally, the Company announces changes to the warrants that it issued on July 4, 2022,...

GREENWICH, Conn. , Sept. 21, 2022 (GLOBE NEWSWIRE) — XPO Logistics, Inc. (NYSE: XPO), a leading provider of freight transportation services, has been named to the 2023 FreightTech 100 by FreightWaves, a global source for supply chain market intelligence. RXO, the planned spin-off of XPO’s tech-enabled brokered transportation platform, was also named to the list. The FreightTech 100 list recognizes the most innovative companies in the transportation industry.  Mario Harik, XPO’s chief information officer and incoming chief executive officer, said, “We’ve spent more than $3 billion on technology over the last 11 years to ensure we’re helping our customers move goods through their supply chains as efficiently as possible. We’re honored to be recognized by FreightWaves for our technological innovation as we move XPO closer to becoming...